Advertisement

Document › Details
ERS Genomics Ltd.. (10/4/18). "Press Release: Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9 License Agreement". Fujisawa & Dublin.
Axcelead Drug Discovery Partners, Inc.(hereinafter referred to as “Axcelead”) and ERS Genomics Limited (hereinafter referred to as “ERS Genomics”) announced today a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology.
Axcelead is the first comprehensive integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded some portion of the drug discovery research department of Takeda Pharmaceutical Company Limited. Axcelead started its business in July of 2017 and offers a comprehensive list of drug discovery services in a broad range of therapeutic areas.
“We look forward to being able to offer our customers an expanded service offering that includes use of this important gene editing technology,” said Yoshinori Ikeura, CEO of Axcelead. “We expect the addition of the CRISPR/Cas9 technology for creation of genetically modified animals or cells to complement our strong capability in non-clinical drug discovery research. These animals or cells are indispensable tools for reliable drug discovery studies including validation of target and proof of concept study.”
“We are pleased to include Axcelead among the rapidly growing list of licensees to this fundamental CRISPR/Cas9 patent portfolio,” commented Eric Rhodes, CEO of ERS Genomics. “This is our first license in Japan following the issuance of our patent in Japan back in May. I would also like to acknowledge the help of Summit Pharmaceuticals International Corporation, our licensing partner in Japan, in putting this agreement in place.”
Dr. Emmanuelle Charpentier’s research unveiled the key components and mechanisms of the CRISPR/Cas9 system that led to the landmark publication with Jennifer Doudna (Jinek, Chylinski et al., 2012), which laid the foundation for the use of CRISPR/Cas9 as a highly versatile and precise genome editing tool.
Axcelead has all the functions related to non-clinical drug discovery research and is also able to draw on the scientific powerhouse of our personnel with expertise, deep knowledge and experience in a range of therapeutic areas through their previous work at Takeda. Axcelead offers a one stop-shop research services with a comprehensive set of best-in-class capabilities to meet a range of customer needs to bridge basic and applied clinical research, from exploratory research to optimizing compounds. Axcelead is based in Fujisawa, Japan. More information can be found at: www.axcelead-ddp.com.
ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology :www.ersgenomics.com.
For ERS Inquiries in Japan
Contact Summit Pharmaceuticals International Corporation
Yoshikazu Ando Ph.D.
Discovery & Alliance Coordination Dept.
alliance@summitpharma.co.jp
For Media
MacDougall Biomedical Communications
Mario Brkulj or Kara Mazey
Direct: +49 89 2420 9345 or +1 781 235 3060
E-Mail: ersgenomics@macbiocom.com
Axcelead Drug Discovery Partners, Inc.
Hiroshi Miki Ph.D.,
Communication, CSO Office
communication@axcelead-ddp.com
Record changed: 2019-06-09 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for ERS Genomics Ltd.
- [1] ExpreS2ion Biotech Holding AB. (7/1/19). "Press Release: ExpreS2ion Licenses Groundbreaking CRISPR/Cas9 Gene Editing Technology from ERS Genomics"....
- [2] ERS Genomics Ltd.. (4/23/19). "Press Release: US Patent Office Grants Charpentier/Doudna Key CRISPR Patent". Dublin....
- [3] ERS Genomics Ltd.. (4/3/19). "Press Release: European Patent Office Grants 3rd Charpentier/Doudna Patent Covering Uses of CRISPR/cas9 in Human and Animal Cells". Dublin....
- [4] ERS Genomics Ltd.. (3/12/19). "Press Release: ERS Genomics Provides Comment on Issuance of University of California CRISPR/Cas9 Patent including Uses of CRISPR »in a Cell«". Dublin....
- [5] ERS Genomics Ltd.. (12/13/18). "Press Release: ERS Genomics and Lonza Enter into CRISPR/Cas9 Technology Licensing Deal". Dublin....
- [6] ERS Genomics Ltd.. (11/1/18). "Press Release: ERS Genomics Licenses CRISPR Gene Editing Technology to DefiniGen to Develop Human Cell Models to Support the Preclinical Development of Therapeutics". Dublin & Cambridge....
- [7] ERS Genomics Ltd.. (10/16/18). "Press Release: ERS Genomics and Syngulon Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Industrial Applications". Dublin & Seraing....
- [8] ERS Genomics Ltd.. (10/4/18). "Press Release: GenAhead Bio and ERS Genomics Enter into CRISPR/Cas9 License Agreement". Fujisawa & Dublin....
- [9] Oxford Genetics Ltd.. (9/20/18). "Press Release: Oxford Genetics Extends Its CRISPR Gene Editing Technology License Agreement from ERS Genomics to Support Its Growth Internationally". Oxford....
- [10] Thermo Fisher Scientific Inc.. (9/18/18). "Press Release: Thermo Fisher Scientific Expands Genome Editing IP Portfolio". Carlsbad, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top